DELAWARE | 001-38241 | 42-1771610 |
(State or Other Jurisdiction of Incorporation or Organization) | (Commission File No.) | (I.R.S. Employer Identification No.) |
q | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
q | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
q | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
q | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | |
ý | Emerging growth company |
ý | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |
Exhibit No. | Description | |
99.1 |
OptiNose, Inc. | ||
By: /s/ Keith A. Goldan | ||
Keith A. Goldan | ||
Chief Financial Officer |
• | Poster 519: EDS-FLU Improves Quality of Life and Health Status: Pooled Analysis of Phase 3 Trials Navigate I and II |
• | Poster 523: Disease Burden of Chronic Rhinosinusitis (CRS) is as Severe as Other Serious Chronic Diseases |
• | Poster 524: Economic Impact Associated with a Reduction in Surgical Eligibility among Adult Patients with Chronic Rhinosinusitis - A Population Cost Offset Model |
• | Poster 527: Exhalation Delivery System with Fluticasone (EDS-FLU) Improves Health-Related Quality of Life (HRQoL) in Patients with Chronic Rhinosinusitis with Nasal Polyps: Results from NAVIGATE II |
• | Poster 534: Exhalation Delivery System with Fluticasone (EDS-FLU) Improves Outcomes in Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) in Patients With or Without Recent Intranasal Steroid Use |
• | Poster 867: Exhalation Delivery Systems (EDS) Greatly Increase Topical Delivery to Target Sites for Chronic Rhinosinusitis (CRS) Compared to Nasal Sprays or Pressurized MDIs (pMDI) |
MO.%OKC^VZFX]RY4TS-CP-26J=)X1XLQAYY>> -N"1+AY$2MI<,+HW
M-&L@K!VKPV5KCJ#AWKJE-2:>5MMQ+G$4'L$:+KMX&IXXUB_H2?">I;O
M[B/XAIXI2?$7-Q>LD)%^:+[QI]I0$?RE5WDC-#CS*CSU^EC>=>]F_P#IVWNI
M[S\U1ZN"_P#EH^=/E
MO.%OKC^VZFX]RY4TS-CP-26J=)X1XLQAYY>> -N"1+AY$2MI<,+HW
M-&L@K!VKPV5KCJ#AWKJE-2:>5MMQ+G$4'L$:+KMX&IXXUB_H2?">I;O
M[B/XAIXI2?$7-Q>LD)%^:+[QI]I0$?RE5WDC-#CS*CSU^EC>=>]F_P#IVWNI
M[S\U1ZN"_P#EH^=/E